Emergent BioSolutions (EBS) News Today $7.72 -1.55 (-16.72%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Comparing Emergent BioSolutions (NYSE:EBS) & BioXcel Therapeutics (NASDAQ:BTAI)November 16 at 2:43 AM | americanbankingnews.comEmergent BioSolutions files to sell 3.61M shares of common stock for holdersNovember 14 at 8:53 PM | markets.businessinsider.comEmergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comEmergent BioSolutions entering ‘turnaround’ phase, new CEO saysNovember 9, 2024 | bizjournals.comEmergent BioSolutions rises 23.7%November 9, 2024 | markets.businessinsider.comEmergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 9, 2024 | finance.yahoo.comEmergent BioSolutions (NYSE:EBS) Stock Price Up 7.9% on Analyst UpgradeEmergent BioSolutions (NYSE:EBS) Shares Up 7.9% Following Analyst UpgradeNovember 8, 2024 | marketbeat.comEmergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa MagicNovember 8, 2024 | seekingalpha.comEmergent BioSolutions Shows Strong Q3 2024 RecoveryNovember 8, 2024 | markets.businessinsider.comEmergent BioSolutions rises 36.1%November 8, 2024 | markets.businessinsider.comEmergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment StrongNovember 8, 2024 | msn.comMpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024November 7, 2024 | benzinga.comEmergent BioSolutions (NYSE:EBS) Shares Gap Up After Analyst UpgradeEmergent BioSolutions (NYSE:EBS) Shares Gap Up After Analyst UpgradeNovember 7, 2024 | marketbeat.comEmergent Biosolutions stock jumps 14% post-market on guidance raiseNovember 7, 2024 | msn.comEmergent BioSolutions (EBS) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comEmergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comEmergent BioSolutions Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comEmergent BioSolutions Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | markets.businessinsider.comEmergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across AfricaNovember 6, 2024 | globenewswire.comEmergent BioSolutions Names Simon Lowry Chief Medical OfficerNovember 6, 2024 | markets.businessinsider.comEmergent BioSolutions appoints Lowry as Chief Medical OfficerNovember 5, 2024 | markets.businessinsider.comEmergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and DevelopmentNovember 5, 2024 | markets.businessinsider.comEmergent BioSolutions (EBS) to Release Earnings on WednesdayEmergent BioSolutions (NYSE:EBS) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638741)October 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys 316,700 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Assenagon Asset Management S.A. boosted its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 74.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 741,552 shares of the biopharmaceutical compOctober 29, 2024 | marketbeat.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBSOctober 25, 2024 | globenewswire.comEmergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024October 23, 2024 | globenewswire.comEmergent BioSolutions (NYSE:EBS) Trading 3.2% Higher - Time to Buy?Emergent BioSolutions (NYSE:EBS) Shares Up 3.2% - Time to Buy?October 21, 2024 | marketbeat.comEBS Emergent BioSolutions Inc.October 20, 2024 | seekingalpha.comZacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and InnodataOctober 16, 2024 | finance.yahoo.comEmergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 84.1% in SeptemberEmergent BioSolutions Inc. (NYSE:EBS - Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 8,230,000 shares, a growth of 84.1% from the September 15th total of 4,470,000 shares. Approximately 15.9% of the shares of the stock are short sold. Based on an average trading volume of 3,020,000 shares, the short-interest ratio is presently 2.7 days.October 12, 2024 | marketbeat.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP decreased its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 37.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 240,768 shares of the biopharmacOctober 12, 2024 | marketbeat.comEmergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024October 11, 2024 | insidermonkey.comEmergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...October 10, 2024 | finance.yahoo.comEmergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid EpidemicOctober 8, 2024 | globenewswire.comAQR Capital Management LLC Has $3.14 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)AQR Capital Management LLC lowered its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 56.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 460,311 shares of the biopharmaceutical company's stock afterOctober 8, 2024 | marketbeat.comRenaissance Technologies LLC Trims Position in Emergent BioSolutions Inc. (NYSE:EBS)Renaissance Technologies LLC cut its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 80.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 173,747 shares of the biopOctober 6, 2024 | marketbeat.comEmergent BioSolutions: Strategic Shifts Present A Turnaround ScenarioOctober 5, 2024 | seekingalpha.com231,014 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Purchased by Squarepoint Ops LLCSquarepoint Ops LLC bought a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 231,014 shares of the biopharmaceutical company's stock, valued at approximately $1,576,0October 5, 2024 | marketbeat.comMarshall Wace LLP Has $3.70 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS)Marshall Wace LLP raised its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 75.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 542,813 shares of the biopharmaceutical company's stock after buying aOctober 3, 2024 | marketbeat.comEmergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan FacilityOctober 3, 2024 | markets.businessinsider.comWhat's Going On With Emergent BioSolutions Stock Wednesday?October 3, 2024 | msn.comRhumbline Advisers Reduces Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Rhumbline Advisers trimmed its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 79.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,624 shares of the biopharmaceutical company's stock afterOctober 1, 2024 | marketbeat.comAmazon to provide opioid overdose drug in workplaceSeptember 28, 2024 | msn.comEmergent Bio gains after U.S. govt. order for smallpox therapySeptember 27, 2024 | msn.comEmergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness EffortsSeptember 26, 2024 | globenewswire.comEmergent Biosolutions Shares Rise 16% on Orders Secured for Smallpox, Monkeypox VaccinesSeptember 25, 2024 | marketwatch.comEmergent Sinks on New Orders for Smallpox, Mpox VaccineSeptember 25, 2024 | baystreet.caEmergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gainsSeptember 25, 2024 | finance.yahoo.comEmergent Bio gains after confirming $400M orders for 2024/25September 25, 2024 | seekingalpha.comEmergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness EffortsSeptember 25, 2024 | globenewswire.com Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> EBS Media Mentions By Week EBS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EBS News Sentiment▼0.290.55▲Average Medical News Sentiment EBS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EBS Articles This Week▼24▲EBS Articles Average Week Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LGND News MNKD News CLDX News DVAX News BCRX News MYGN News NVAX News INVA News OPK News IRWD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:EBS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.